Previous researches have reported that decline of albumin on admission is a predictor of adverse outcomes,[11,13,23–25] while a higher albumin level at admission predicts a better prognosis for COVID-19 patients.[12] Additionally, Xie et al identified the turning point of serum albumin levels; however, their study population ranged in age from 16 to 93 years, and the serum albumin measured was the initial albumin level upon admission.[26] However, it is unlikely for clinicians to alter the initial albumin levels at admission. This evidence concerns the gene ALB and COVID-19.